Methods Of Treating New-onset Plaque Type Psoriasis Using Il-17 Antagonists

Abstract

The present disclosure relates to methods for treating new-onset plaque-type psoriasis patients and inhibiting the progression of structural damage in these patients, using IL-17 antagonists, e.g., secukinumab. Also disclosed herein are uses of IL-17 antagonists, e.g., IL-17 antibodies, such as secukinumab, for treating new-onset plaque-type psoriasis patients, as well as medicaments, dosing regimens, pharmaceutical formulations, dosage forms, and kits for use in the disclosed uses and methods.


Claims
Download PDF
Document Preview
Document History
  • Publication: Jan 25, 2018
  • Application: Jul 18, 2017
    WO IB 2017054333 W
  • Priority: Jul 19, 2016
    US US 201662364007 P

Sign in to the Lens

Feedback